Broadcom Inc (AVGO) Stock Price Today
Aura AI Summary
Key Stats
- $1.81TMarket Cap
- -Volume
- TechnologySector
- $481.5752W High
- $289.6052W Low
- -Typical Hold Time
- $1.85TEnterprise Value
- 0.68%Div Yield
- -Trading Activity
Track Broadcom Inc (AVGO) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Broadcom Inc has traded between a low of $289.6 and a high of $481.57, highlighting its annual price range. Buy and sell Broadcom Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Broadcom Inc
Broadcom--the combined entity of Broadcom and Avago--boasts a highly diverse product portfolio across an array of end markets. Avago focused primarily on radio frequency filters and amplifiers used in high-end smartphones, such as the Apple iPhone and Samsung Galaxy devices, in addition to an assortment of solutions for wired infrastructure, enterprise storage, and industrial end markets. Legacy Broadcom targeted networking semiconductors, such as switch and physical layer chips, broadband products (such as television set-top box processors), and connectivity chips that handle standards such as Wi-Fi and Bluetooth. The company has acquired Brocade, CA Technologies, Symantec's enterprise security business, and has a pending deal to acquire VMware to bolster its offerings in software.
Most Recent News
Director Carande buys 2,101 shares of United Community Banks, signaling confidence.
Director Carande has purchased 2,101 shares of United Community Banks. This insider buying may indicate confidence in the company's future prospects. Investors often view such transactions as a positive signal, potentially influencing market sentimen...

Abnormal AI expands OpenAI partnership to enhance cybersecurity with advanced AI tools
Abnormal AI is broadening its partnership with OpenAI to enhance its Behavioral AI cybersecurity products that protect over 4,500 organizations, including a quarter of the Fortune 500. The collaboration will integrate OpenAI's advanced models and Cod...

Merck stock hits record high after positive melanoma vaccine trial results with Moderna
Merck & Co. surged to all-time highs following positive Phase 3 trial results of its melanoma vaccine developed with Moderna. The company maintains a Buy rating due to strong growth in oncology, solid free cash flow, and potential for further stock g...

People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.